Short answer
Denali Therapeutics Inc. (DNLI) filed an 8-K current report with the SEC on June 4, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). 86.96% of outstanding shares participated, providing strong representation at Denali’s annual meeting.
Denali Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 86.96% of outstanding shares participated, providing strong representation at Denali’s annual meeting
- Jennifer Cook, David Schenkein, and Ryan Watts elected as Class III directors through the 2029 annual meeting
- Ryan Watts received strongest support, with 121,220,572 votes for and 3,624,716 withheld
- Ernst & Young LLP ratified as independent auditor for fiscal 2026, with 137,516,267 votes for
- Executive compensation approved advisory basis, with 117,038,745 votes for and 7,088,810 against
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Denali Therapeutics Inc. 8-K filings
Get the next DNLI 8-K as it lands
Follow DNLI for push alerts, or ask the research agent what this filing means.